10-Q quarterly report · filed Nov 4, 2026

Dianthus Therapeutics, Inc. /DE/ (DNTH) Q3 2026 10-Q Quarterly Report

Short answer

Dianthus Therapeutics, Inc. /DE/ (DNTH) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $12M (up 2966.4% year over year) with net income of −$47M.

Q3 2026 key financials · XBRL

Revenue
$12M
+2966.4% YoY · +5.2% QoQ
Net income
−$47M
−26.9% YoY · +7.1% QoQ
Operating margin
-481.5%
EPS (diluted)
−$0.81
+16.5% YoY · +10.0% QoQ

Source: XBRL data from the Dianthus Therapeutics, Inc. /DE/ (DNTH) Q3 2026 10-Q on SEC EDGAR. USD.

Dianthus Therapeutics, Inc. /DE/ Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $1.2M vs $0.4M YoY, up $0.8M from reimbursable claseprubart trial costs
  • Operating margin not meaningful, operating loss $58.5M vs $40.3M YoY
  • R&D expenses $45.6M vs $32.5M, driven by claseprubart trials and DNTH212/DNTH312 discovery
  • Operating cash flow used $128.2M through nine months, vs $82.1M YoY
  • Cash, equivalents and investments $1.2B, funding expected into 2030; CAPTIVATE results projected by year-end 2027

Risk Factors

  • No material changes to risk factors from the December 31, 2025 Form 10-K
  • Carried-forward risk: unidentified risks could materially harm business, financial condition, results and growth prospects
  • Market risk: adverse developments could reduce the market price of common stock

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Dianthus Therapeutics, Inc. /DE/ quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.